share_log

Hydreight Updates on VSDHOne: Revolutionizing Direct-to-Consumer Healthcare Across All 50 States

Hydreight Updates on VSDHOne: Revolutionizing Direct-to-Consumer Healthcare Across All 50 States

Hydreight关于VSDHOne的更新:在所有50个州彻底改变直接面向消费的医疗保健
GlobeNewswire ·  12/16 20:00

VANCOUVER, British Columbia and LAS VEGAS, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. ("Hydreight"or the "Company")(TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6), a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is providing an update on VSDHOne, its Direct-to-Consumer (D2C) healthcare platform. Now fully operational in all 50 states, VSDHOne is redefining telehealth by offering businesses an unparalleled, end-to-end solution to launch their own healthcare brands—quickly, cost-effectively, and at scale.

温哥华,不列颠哥伦比亚省和拉斯维加斯,2024年12月16日(环球新闻稿)-- Hydreight Technologies Inc. ("Hydreight"或 "公司")(TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6),一个快速发展的移动临床网络和医疗平台,为美国50个州提供灵活的家庭医疗服务,正在就VSDHOne,旗下的直接面向消费者(D2C)医疗平台进行更新。现在在所有50个州全面运营,VSDHOne通过为企业提供无与伦比的端到端解决方案,重新定义远程医疗,使其能够迅速、经济高效地推出自己的医疗品牌。

What is VSDHOne?

什么是VSDHOne?

VSDHOne provides a comprehensive telemedicine platform that empowers businesses, including MedSpas, health and wellness entrepreneurs, retailers, and pharmaceutical brands, to create D2C healthcare solutions in days rather than months. The purpose of launching VSDHOne is to make it easy for any existing brick and mortar or individuals to launch a direct to consumer healthcare brand in a few weeks without worrying about compliance, doctor network, telemedicine and ecommerce Technology, Medical direction and oversight, Pharmacy network, and a medical legal framework in all 50 States.

VSDHOne提供一个全面的远程医疗平台,赋能企业,包括医疗水疗中心、健康和保健创业者、零售商以及药品品牌,在几天内而非几个月内创建D2C医疗解决方案。推出VSDHOne的目的是让任何现有的实体店或个人在几周内轻松推出直接面向消费者的医疗品牌,而无需担心合规性、医生网络、远程医疗及电子商务科技、医疗方向和监督、药房网络,以及在所有50个州的医疗法律框架。

With the marriage of Virtual and at facility healthcare features, Companies can expand beyond their current Bricks and Mortar solutions.

通过虚拟和实体医疗功能的结合,公司可以超越现有的实体解决方案进行扩展。

Features include:

功能包括:

  • eCommerce Platform
  • Telemedicine Technology
  • Booking and Scheduling Technology
  • Nationwide Doctors Network in all 50 States
  • Pharmacy Network and fulfillment partners
  • Medical Direction
  • Medical Legal Structure
  • Payment Processing
  • LegitScript approved - Enterprise Partner
  • Affiliate Marketing Automation
  • 电子商务平台
  • 远程医疗技术
  • 预定和调度科技
  • 覆盖所有50州的全国医生网络
  • 药品网络和履约合作伙伴
  • 医疗指导
  • 医疗法律结构
  • 支付处理
  • LegitScript批准 - 企业合作伙伴
  • Affiliate营销自动化

"VSDHOne bridges the gap in healthcare accessibility, empowering nontraditional players to deliver personalized, convenient care directly to consumers. This isn't just telemedicine; it's Telehealth 2.0," said Shane Madden, CEO, Hydreight Technologies.

"VSDHOne打破了医疗服务的可及性障碍,使非传统参与者能够直接向消费者提供个性化、便捷的护理。这不仅仅是远程医疗;这就是Telehealth 2.0," Hydreight Technologies首席执行官Shane Madden说道。

Available Treatments on the platform:

平台上的可用治疗方案:

There are currently about 40 products available on the platform for the clients to offer to their patients. VSDHOne supports a wide range of treatments tailored to meet growing consumer demand for convenient, personalized care. The platform currently offers:

目前平台上约有40种产品可供客户提供给他们的病人。VSDHOne支持广泛的治疗方案,以满足日益增长的消费对方便个性化护理的需求。该平台目前提供:

  • Skincare Treatments: Including acne and anti-aging solutions.
  • Hair Loss Treatments: Clinically-backed therapies to promote hair regrowth.
  • Sexual Health: Addressing common concerns with effective, discreet care.
  • Hormone Replacement Therapy: Including Sermorelin and Testosterone Replacement Therapy (TRT).
  • GLP-1 Weight Management: Cutting-edge treatments for obesity and weight management.
  • Peptides
  • 皮肤护理治疗:包括痤疮和抗衰老解决方案。
  • 脱发治疗:经过临床验证的疗法以促进头发再生。
  • 性健康:针对常见问题提供有效、私密的护理。
  • 激素替代治疗:包括Sermorelin和睾酮替代疗法(TRT)。
  • GLP-1体重管理:针对肥胖和体重管理的最前沿治疗。

Future Treatments Coming to the Platform

未来将有治疗方案进入平台

Hydreight continues to expand VSDHOne's offerings to include innovative therapies:

Hydreight继续扩展VSDHOne的服务,以包括创新疗法:

  • Genetic Testing
  • Birth Control Options
  • Oral GLP-1 Therapies
  • NAD+ Nasal Spray for anti-aging and energy
  • Longevity-focused solutions
  • 基因检测
  • 避孕期权
  • 口服GLP-1疗法
  • NAD+鼻用喷雾用于抗衰老和能量提升
  • 专注于长寿的解决方案

These treatments position VSDHOne as a comprehensive solution for a wide array of consumer healthcare needs, creating opportunities for businesses to grow their offerings and drive recurring patient engagement.

这些治疗使VSDHOne成为满足广泛消费医疗需求的综合解决方案,为企业拓展产品提供了机会,并推动患者的重复参与。

Current Market and Its Gaps:

当前市场及其缺口:

Consumer trust in the healthcare system is at an all-time low. This is due to equal access to care and pricing. In certain states, there remains a significant limitation in accessing healthcare professionals. More than 80% of counties across the country lack access to services needed to maintain, much less improve, their health. That's approximately 30 million Americans who live in "healthcare deserts" where accessible physicians are scarce.

消费者信任 在医疗系统中的信任处于历史最低水平。这是因为护理和定价的平等获取。在某些州,仍然存在获取医疗专业人员的重大限制。 超过 全国各地缺乏维持健康所需的服务,更不用说改善健康了。大约有 3000万 美国人生活在“医疗服务沙漠”中,那里医生资源稀缺。

Since the COVID-19 pandemic, the demand for telemedicine has surged, with adoption rates among physicians rising from 15.4% in 2019 to 86.5% in 2021. As telehealth continues to evolve, providers are expanding their services to include everything from live consultations to asynchronous treatments.

自新冠疫情以来,远程医疗的需求激增,医生的采用率从2019年的15.4%上升到2021年的86.5%。随着远程医疗的不断发展,提供者正在扩大他们的服务,包括从现场咨询到异步治疗的所有内容。

There are many online providers for these treatments but they either are using different providers for different needs or they may not follow the best practices to have the full compliance. VSDHOne empowers providers from online providers, health clubs to existing brick and mortar locations to expand their offerings to consumers directly without being worried about the medical operational side of the offerings. They place a widget on their website and as soon as a patient lands on their website, they will go through the VSDHOne widget step by step platform and will receive their treatments and medications.

这些治疗有许多在线提供者,但他们要么使用不同的提供者来满足不同的需求,要么可能没有遵循最佳实践以确保完全合规。VSDHOne使在线提供者、健康俱乐部和现有实体地点的提供者能够直接向消费者扩展他们的产品,而无需担心医疗运营方面的内容。他们在自己的网站上放置一个小部件,当患者访问他们的网站时,将按照VSDHOne小部件的步骤逐步进行,并获得治疗和药物。

A Compelling Business Model:

引人注目的商业模式:

VSDHOne operates on a SaaS-based model, with customers purchasing state-specific licenses and paying per-order fees for the platform's end-to-end capabilities. This provides Hydreight with a recurring revenue stream while offering clients unparalleled scalability.

VSDHOne 基于SaaS-云计算模型运作,客户购买特定州的许可证并为平台的端到端能力支付按订单费用。这为Hydreight提供了一个经常性营业收入来源,同时为客户提供了无与伦比的可扩展性。

Since its soft launch in late Q2 2024, VSDHOne has been onboarding over 200 licenses, far exceeding expectations. The platform and management projects to have over 1,000 licenses by December 2025, creating significant recurring revenue opportunities.

自2024年第二季度末进行软启动以来,VSDHOne已成功接入超过200个许可证,远超预期。该平台及管理层预计到2025年12月将拥有超过1,000个许可证,从而创造显著的经常性营业收入机会。

VSDHOne team is projecting each license to process approximately between 5 to 20 orders per day after full onboarding. The company will aim to provide guidance to the market by the end of Q1 after fully onboarding the first group of licenses and monitoring their traction in the first months. Most of the orders and treatments are ongoing treatments that patients need to have follow up orders every month after the initial month.

VSDHOne团队预计,经过全面接入后,每个许可证每天处理的订单大约在5到20个之间。公司计划在第一季度末向市场提供指导,届时将完全接入第一批许可证并监测它们在初期几个月的增长情况。大多数订单和治疗是患者需要在初始月份后每个月进行跟进的持续治疗。

"Hims & Hers Health, Inc. reported that it processed approximately 2.66 million net orders with an Average Order Value ("AOV") of approximately $147 in the third quarter of 2024. This translates to an average of about 29,600 orders per day during that quarter. We are helping other vendors to have such infrastructure to offer similar services without being worried about the details of offering and operations" said Shane Madden, CEO, Hydreight Technologies.

"Hims & Hers Health, Inc. 报告称,在2024年第三季度其处理了大约266万笔净订单,平均订单价值("AOV")约为147美元。这相当于该季度每天约29,600笔订单。我们正在帮助其他供应商拥有这样的制造行业基础设施,以便提供类似的服务,而不必担心提供和运营的细节",Hydreight Technologies的首席执行官Shane Madden说道。

WEBINAR:

网络研讨会:

The Company's management, and Medical team will be hosting a webinar to discuss more details about this in January 2025.

公司的管理层和医疗团队将于2025年1月举办网络研讨会,以讨论更多相关细节。

For more information or to get started, please email business@vsdigitalhealth.com.

如需更多信息或开始,请发送电子邮件 business@vsdigitalhealth.com.

About VSDHOne - Direct to Consumer Platform
In a partnership with two other parties, Hydreight Technologies launched the VSDHOne (Read as VSDH-One)platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s (semaglutide, tirzepatide), peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy ("TRT"), hair loss, skincare, sexual health and more.

关于VSDHOne - 直接面向消费者的平台
Hydreight Technologies与另外两个合作方合作推出了VSDHOne(读作VSDH-One)平台。VSDHOne简化了公司和医疗水疗业务进入合规在线医疗空间的挑战。该平台将帮助所有业务在所有50个州内在几天内推出直接面向消费者的医疗品牌。合规产品包括:GLP-1(赛美特肽,替尔塞肽),肽类,个性化医疗治疗,瑟莫瑞林,睾酮替代疗法("TRT"),脱发,护肤,性健康等。

Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.

Hydreight投资了科技、法律和基础设施来推出这个平台。VSDHOne平台为希望推出直接面向消费者的医疗品牌的企业提供了完整的一站式解决方案。从合规和远程医疗科技到全国性的医生和药房网络,VSDHOne提供了进入在线医疗空间所需的所有工具。该平台旨在显著减少启动此类服务所涉及的时间和成本,使企业能够在几天内而非几个月内上线。

About Hydreight Technologies Inc.

关于Hydreight科技公司。

Hydreight Technologies Inc. is building one of the largest mobile clinic network in the United States. Its proprietary, fully integrated platform hosts a network of over 2500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.

Hydreight科技公司正在建立美国最大的移动诊所网络之一。其专有的全方位整合平台拥有超过2500名护士、100多名医生以及覆盖50个州的药房网络。该平台包括一套内置的易于使用的全方位工具,用于会计、文档、销售、库存、预订和管理患者数据,这使得获得许可的医疗专业人员能够直接为患者在家、办公室或酒店提供服务。Hydreight正在弥合提供者合规性与患者便利性之间的差距,赋能护士、医疗水疗技术人员和其他获得许可的医疗专业人员。Hydreight平台允许医疗专业人员独立按照自己的条件提供服务,或将移动服务添加到现有的位置基础运营中。Hydreight拥有一个5030亿的药房网络,服务于所有50个州,并与美国认证的电子处方和远程医疗提供者网络密切相关。

On behalf of the Board of Directors

谨代表董事会

Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.

肖恩·马登
董事长兼首席执行官:Jeremiah R. Young。
Hydreight Technologies Inc.

Contact
Email: ir@hydreight.com; Telephone: 1 (702) 970-8112

联系
电子邮件: ir@hydreight.com;电话:1 (702) 970-8112

This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

本新闻稿不构成在美国销售证券的要约。所提供的证券尚未,也不会根据1933年美国证券法(经修订)进行注册,因此在没有美国注册或适用的美国注册要求豁免的情况下,不能在美国提供或出售这些证券。

Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

TSXV及其监管服务提供商(如TSXV政策中定义的那样)均不对本公告的充分性或准确性负责。本新闻稿不构成在美国出售证券的要约。所提供的证券未根据1933年修订版的美国证券法进行注册,也不会在未经美国注册或适用豁免规定的情况下在美国境内提供或销售。

Cautionary Note Regarding Forward-Looking Information

关于前瞻性信息的警示说明

This press release contains statements which constitute "forward-looking information" within the meaning of applicable securities laws, including statements regarding the plans, path to profitability, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "projecting", "expect" or similar expressions and includes information regarding expectations for the Company's growth, VSDHone's number of licenses and orders in 2025.

本新闻稿包含符合适用证券法定义的“前瞻性信息”的声明,包括关于公司未来商业活动和运营表现的计划、盈利能力的路径、意图、信念和当前预期的声明。前瞻性信息通常通过“可能”、“将”、“可以”、“应该”、“会”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“期待”或类似表达来识别,并包括关于公司增长、VSDHone在2025年的许可证和订单数量的预期信息。

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company's shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.

投资者需谨慎,前瞻性信息并非基于历史事实,而是反映公司管理层对未来结果或事件的预期、估计或预测,这些预期基于管理层在作出声明时认为合理的意见、假设和估计。尽管公司相信这些前瞻性信息中反映的预期是合理的,但此类信息涉及风险和不确定性,不应过分依赖,因为未知或不可预测的因素可能对公司未来的结果、表现或成就产生重大不利影响。可能导致实际结果与前瞻性信息中预测结果显著不同的关键因素包括:获得公司运营的业务所需的监管和其他批准的能力,和/或公司股份在TSXV上市对关系的潜在影响,包括与监管机构、员工、供应商、客户和竞争对手的关系;一般经济、商业和政治状况的变化,包括金融市场的变化;适用法律的变化;遵守广泛的政府法规;以及作为上市公司的管理时间的转移。此前瞻性信息可能会受到公司业务和市场条件中的风险和不确定性的影响。

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

如果这些风险或不确定性中的一个或多个实现,或者支撑前瞻性信息的假设被证明不正确,实际结果可能与此处所描述的意图、计划、预期、相信、估计或期待的结果有重大差异。虽然公司已试图识别可能导致实际结果与预期、估计或意图有重大差异的重要风险、不确定性和因素,但可能还存在其他因素也会导致结果未能如预期、估计或意图。除非适用法律另有要求,公司不打算并不承担任何更新该前瞻性信息的义务。


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发